🔎 Trials Near Me

Avaleht › Crohni tõbi › Washington

Crohni tõbi kliinilised uuringud osariigis Washington

22 uuringut haiguse Crohni tõbi jaoks otsivad osalejaid osariigis Washington.

Linnad osariigis Washington

Ametlik uuringutekst (inglise keeles)

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

  • Washington Gastroenterology - Tacoma ( Site 0295), Tacoma
VärbamineFaas 3
Kõik vanused · Kõik sood · Uuendatud 2. okt 2026 · NCT06651281

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • University of Washington ( Site 5115), Seattle
  • Washington Gastroenterology - Tacoma ( Site 5004), Tacoma
VärbamineFaas 3
Vanused 16–80 · Kõik sood · Uuendatud 2. okt 2026 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Washington Gastroenterology - Bellevue /ID# 283966, Bellevue
  • Washington Gastroenterology - Tacoma /ID# 284143, Tacoma
  • The Vancouver Clinic /ID# 280497, Vancouver
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 2. okt 2026 · NCT07697456

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • GI Alliance, Bellevue
VärbamineFaas 4
Vanused 18–80 · Kõik sood · Uuendatud 30. sept 2026 · NCT06581328

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • Virginia Mason Hospital and Medical Center /ID# 265574, Seattle
  • Washington Gastroenterology - Tacoma /ID# 267302, Tacoma
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 25. sept 2026 · NCT06548542

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  • GI Alliance Tacoma, Tacoma
VärbamineFaas 2/3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT07196722

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  • University of Washington Medical Center, Seattle
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 25. sept 2026 · NCT06233461

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Washington Gastroenterology - Tacoma, Tacoma
VärbamineFaas 3
Vanused 18–70 · Kõik sood · Uuendatud 24. sept 2026 · NCT06937099

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • GI Alliance - Bellevue-Site Number: 8400143, Bellevue
  • The Vancouver Clinic Inc. P.S.-Site Number: 8400090, Vancouver
VärbamineFaas 3
Vanused 16–80 · Kõik sood · Uuendatud 23. sept 2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • The Vancouver Clinic Inc. P.S.-Site Number: 8400090, Vancouver
VärbamineFaas 3
Vanused 16–80 · Kõik sood · Uuendatud 23. sept 2026 · NCT07184944

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

  • Washington Gastroenterology- GIA, Tacoma
VärbamineFaas 4
Vanused 18–70 · Kõik sood · Uuendatud 9. sept 2026 · NCT06045754

Familial Inflammatory Bowel Disease Early Risk

  • Seattle Children's Hospital, Seattle
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
Vanused 0–55 · Kõik sood · Uuendatud 28. aug 2026 · NCT07791862

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  • GI Alliance Tacoma, Tacoma
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 28. aug 2026 · NCT07577843

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  • Seattle Children's Hospital, Seattle
VärbamineFaas 3
Vanused 2–17 · Kõik sood · Uuendatud 24. aug 2026 · NCT05509777

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

  • MultiCare Institute for Research & Innovation, Tacoma
VärbamineFaas 3
Vanused 2–17 · Kõik sood · Uuendatud 3. aug 2026 · NCT06100289

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • Multicare Health System Institute for Research and Innovation, Tacoma
VärbamineFaas 3
Vanused 2–17 · Kõik sood · Uuendatud 22. juuni 2026 · NCT06405087

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

  • Seattle Children's Hospital, Seattle
VärbamineFaas 4
Vanused 6–17 · Kõik sood · Uuendatud 27. mai 2026 · NCT05781152

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  • Swedish Cancer Institute, Seattle
  • University of Washington Medical Center - Montlake, Seattle
VärbamineFaas 3
Vanused 18–65 · Kõik sood · Uuendatud 27. mai 2026 · NCT06227910

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  • University of Washington, Seattle
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 27. apr 2026 · NCT06456593

Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)

  • Seattle Children's Hospital, Seattle
VärbamineVaatlusuuring
Vanused 6–21 · Kõik sood · Uuendatud 24. apr 2026 · NCT06315179

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, Bellevue
  • Mirador Therapeutics Selected Site, Silverdale
  • Mirador Therapeutics Selected Site, Tacoma
VärbamineFaas 2
Vanused 18–80 · Kõik sood · Uuendatud 12. märts 2026 · NCT07113522

Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial

  • Seattle Children's Hospital, Seattle
Värbamine
Vanused 8–21 · Kõik sood · Uuendatud 12. juuni 2025 · NCT06216899

Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.